ipriflavone has been researched along with Hyperparathyroidism in 3 studies
ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism." | 7.68 | Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. ( Carnevale, V; Mazzuoli, G; Minisola, S; Pacitti, MT; Romagnoli, E; Rosso, R; Scarda, A; Scarnecchia, L, 1992) |
| "Ipriflavone, an isoflavone synthesized from the soy isoflavone daidzein, holds great promise in the prevention and treatment of osteoporosis and other metabolic bone diseases." | 4.80 | Ipriflavone: an important bone-building isoflavone. ( Head, KA, 1999) |
| "The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism." | 3.68 | Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. ( Carnevale, V; Mazzuoli, G; Minisola, S; Pacitti, MT; Romagnoli, E; Rosso, R; Scarda, A; Scarnecchia, L, 1992) |
| "Ipriflavone (IP) is an isoflavone derivative available in several countries for investigational and/or therapeutic use." | 2.38 | Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. ( Reginster, JY, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reginster, JY | 1 |
| Head, KA | 1 |
| Mazzuoli, G | 1 |
| Romagnoli, E | 1 |
| Carnevale, V | 1 |
| Scarda, A | 1 |
| Scarnecchia, L | 1 |
| Pacitti, MT | 1 |
| Rosso, R | 1 |
| Minisola, S | 1 |
2 reviews available for ipriflavone and Hyperparathyroidism
| Article | Year |
|---|---|
Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
Topics: Animals; Bone Resorption; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Hyperpar | 1993 |
Ipriflavone: an important bone-building isoflavone.
Topics: Bone Remodeling; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism; Isoflavones; Osteit | 1999 |
1 other study available for ipriflavone and Hyperparathyroidism
| Article | Year |
|---|---|
Effects of ipriflavone on bone remodeling in primary hyperparathyroidism.
Topics: Adult; Aged; Bone Remodeling; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hyperparathyroidi | 1992 |